THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [11.26] ID: TIP-MED-000230 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Lithium Carbonate (Mood Stabiliser — Narrow Therapeutic Index)

Active Ingredient / Scientific Identity: Lithium Carbonate • Class: Monovalent Cation Mood Stabiliser (Inositol Monophosphatase & GSK-3beta Inhibitor)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Lithium Carbonate (Mood Stabiliser — Narrow Therapeutic Index) ([11.26] | ID: TIP-MED-000230) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/11-26-lithium-carbonate-mood-stabiliser-narrow-therapeutic-index/
Generic / Entity NameLithium Carbonate (Mood Stabiliser — Narrow Therapeutic Index) ([11.26])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassMonovalent Cation Mood Stabiliser (Inositol Monophosphatase & GSK-3beta Inhibitor)
Available Dosage FormsImmediate-Release Tablet/Capsule: 150 mg, 300 mg; Prolonged-Release (SR/CR) Tablet: 400 mg, 450 mg.
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Excreted >95% unchanged by kidneys (reabsorbed in proximal tubule alongside sodium). eGFR 30-50 mL/min: 50-75% of norm
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Lithium Carbonate (Mood Stabiliser — Narrow Therapeutic Index) (TIP-MED-000230, Reference Code [11.26]) is classified under CNS & Psychiatric Medicines (Ch 11) as a Monovalent Cation Mood Stabiliser (Inositol Monophosphatase & GSK-3beta Inhibitor). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.26], p. 152): Licab, Lithosun, Intalith-CR — Strengths & Dosage Forms: Immediate-Release Tablet/Capsule: 150 mg, 300 mg; Prolonged-Release (SR/CR) Tablet: 400 mg, 450 mg.
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.26], p. 152): Licab, Lithosun, Intalith-CR — Strengths & Dosage Forms: Immediate-Release Tablet/Capsule: 150 mg, 300 mg; Prolonged-Release (SR/CR) Tablet: 400 mg, 450 mg.
Dosage Forms & Available Strengths:
Immediate-Release Tablet/Capsule: 150 mg, 300 mg; Prolonged-Release (SR/CR) Tablet: 400 mg, 450 mg.
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Modulates intracellular second-messenger phosphatidylinositol (depletes free myo-inositol) and inhibits glycogen synthase kinase-3beta (GSK-3beta), promoting neuroprotection and mood stabilisation.

4. Therapeutic Indications & Evidence-Supported Uses

  • Acute mania and long-term prophylaxis of bipolar I/II disorder
  • anti-suicidal agent in mood disorders
  • augmentation in treatment-resistant depression

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adult: Start 300 mg BD/TDS (or 400-450 mg SR BD); adjust according to 12-hour trough serum lithium level (typical maintenance 600-1200 mg/day). • Paediatric: Bipolar I (>=12 yr): Titrate strictly by 12-hour trough serum levels and weight.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Excreted >95% unchanged by kidneys (reabsorbed in proximal tubule alongside sodium). eGFR 30-50 mL/min: 50-75% of normal dose with frequent TDM; eGFR <30 mL/min: Generally contraindicated. • Hepatic: Not metabolised by liver; however, cirrhotic ascites and sodium restriction alter lithium clearance—avoid.
Elimination & Renal Adjustment:
Renal: Excreted >95% unchanged by kidneys (reabsorbed in proximal tubule alongside sodium). eGFR 30-50 mL/min: 50-75% of normal dose with frequent TDM; eGFR <30 mL/min: Generally contraindicated. • Hepatic: Not metabolised by liver; however, cirrhotic ascites and sodium restriction alter lithium clearance—avoid.
Hepatic Impairment Considerations:
Renal: Excreted >95% unchanged by kidneys (reabsorbed in proximal tubule alongside sodium). eGFR 30-50 mL/min: 50-75% of normal dose with frequent TDM; eGFR <30 mL/min: Generally contraindicated. • Hepatic: Not metabolised by liver; however, cirrhotic ascites and sodium restriction alter lithium clearance—avoid.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Severe renal failure, severe cardiovascular disease, untreated hypothyroidism, severe dehydration or sodium depletion (Addison's disease, low-salt diet), Brugada syndrome, 1st-trimester pregnancy if avoidable. • Precautions: NARROW THERAPEUTIC INDEX: Therapeutic 12-hour trough = 0.6–1.0 mmol/L (0.8–1.2 mmol/L in acute mania); Toxicity >1.5 mmol/L; Severe/Lethal >2.0–2.5 mmol/L. Dehydration (summer heat, diarrhoea, fever, diuretics) triggers acute lithium toxicity.

Key Clinical Precautions: Renal: Excreted >95% unchanged by kidneys (reabsorbed in proximal tubule alongside sodium). eGFR 30-50 mL/min: 50-75% of normal dose with frequent TDM; eGFR <30 mL/min: Generally contraindicated. • Hepatic: Not metabolised by liver; however, cirrhotic ascites and sodium restriction alter lithium clearance—avoid.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Fine postural hand tremor, polyuria/polydipsia, weight gain, mild GI upset, acne/psoriasis flare.
  • Lithium toxicity (coarse tremor, ataxia, dysarthria, vomiting, confusion, seizures, coma), hypothyroidism, nephrogenic diabetes insipidus, hyperparathyroidism.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Thiazide diuretics (Hydrochlorothiazide, Chlorthalidone) / ACE inhibitors / ARBs / NSAIDs (Ibuprofen, Diclofenac, Etoricoxib) -> reduce renal lithium clearance by 25-50% and precipitate acute lithium toxicity; SSRIs -> serotonin toxicity

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Maintain consistent daily fluid (2.5-3 L/day) and dietary salt intake; never take over-the-counter painkillers (NSAIDs like Brufen/Voveran) without medical advice; stop lithium and seek urgent care if persistent vomiting, diarrhoea, coarse shaking, or slurred speech occurs.
  • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
  • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
  • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Immediate-Release Tablet/Capsule: 150 mg, 300 mg; Prolonged-Release (SR/CR) Tablet: 400 mg, 450 mg.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 11 [11.26] (p. 152)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/11-26-lithium-carbonate-mood-stabiliser-narrow-therapeutic-index/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.